CRISPR Therapeutics (CRSP) has been making waves lately, especially after announcing promising early clinical data for its ...

CRISPR Therapeutics AG is a long-term buy despite slow Casgevy uptake. Click for my updated look at CRSP earnings and the ...

Regulatory approvals for Crispr Therapeutics' CASGEVY program are increasing, expanding the potential market for the treatment. Government support, including public funds, is likely to be available ...

Discover the top CRISPR companies driving innovation in gene editing, from biotech pioneers to promising start-ups shaping ...

SAN DIEGO--(BUSINESS WIRE)--CRISPR QC, a biotechnology start-up based in San Diego, is pleased to announce a major stride in its ongoing Series A funding round. Known for their CRISPR Analytics ...

-CASGEVY® momentum building; >75 authorized treatment centers (ATCs) activated globally, achieving the target goal and ~115 patients have had cells collected across all regions; positioning the ...

About SRSD107 SRSD107 is a novel double-stranded small interfering ribonucleic acid (siRNA), that is designed to target the human coagulation factor XI (FXI) mRNA and inhibit FXI protein expression.

* Maxcyte will supply systems Co and Casebia as part of license agreement and will receive upfront, milestone, and sales-based payments * Says commercial license builds on an existing research and ...

Scientists edited grape cells with CRISPR to boost resveratrol output, offering a cleaner and more sustainable alternative to ...